showcasing an innovation in preclinical screening using cancer patient-derived organoids. This service is part of a strategy to replace animal testing, significantly enhance the accuracy of predicting drug candidate responses, and officially enter the global CRO market. Through collaboration with Samsung Medical Center, Samsung Biologics has secured a large-scale cancer organoid library based on 4.5 million clinical data points and patient tissues. Notably, it has demonstrated over 85% similarity to patient responses in pancreatic cancer models, proving to be significantly more cost- and time-efficient than traditional animal models. The service is a one-stop package that includes drug screening, integrated analysis of genomic and pathological data, and consultation with clinical specialists, capable of delivering results in approximately five weeks. FDA and EMA policies encouraging the reduction of animal testing are positively impacting global market expansion, and the service has garnered significant interest, with over 150 meetings with pharmaceutical companies held immediately after its launch. Samsung Biologics plans to integrate its existing ADC and AAV CDMO portfolios with organoid-based CRO services to strengthen personalized preclinical evaluation based on precision medicine. By expanding its business beyond a global top-tier CDMO to include CRO services, the company is enhancing its innovative competitiveness through a partnership-centric long-term strategy. Organoids are 'mini-organ models' created by 3D culture of stem cells or patient tissues, offering high reproducibility of human responses and cost-efficiency. Pathological and clinical experts from Samsung Medical Center directly participate in data interpretation, increasing scientific reliability. This platform is expected to become a core platform for precision medicine and data-driven drug development in the future. From HADD Science's perspective, this is a prime example of the potential for patient-specific therapeutic development and integration with AI and bio big data, symbolizing an innovation that strengthens the global competitiveness of the Korean bio-industry.